---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-25-000097"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:33:58.772760+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q2 revenue $339.5M (+13.4% YoY); net income $45.3M vs prior-year loss

## Summary
- Revenue $339.5M, +13.4% YoY; U.S. Thrombectomy $188.5M (+22.6%); U.S. VTE +42%.
- Net income $45.3M vs loss from operations of $81.0M in Q2 2024; operating margin 12.0%.
- Adjusted EBITDA $61.4M (18.1% margin); gross margin improved to 66.0% from 54.4% (ex $33.4M one-time charge).

## SEC filing metadata
- accession: 0001321732-25-000097
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173225000097/0001321732-25-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173225000097/pen-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-25-000097
- JSON: https://secwatch.observer/filing/0001321732-25-000097.json
- Plain text: https://secwatch.observer/filing/0001321732-25-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.